ACUTE EFFECT OF INDACATEROL IN CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): A RANDOMIZED CONTROLLED TRIAL

Abstract

Introduction:Bronchodilatorsarethemaintreatmentofchronicobstructivepulmonarydisease(COPD). Theindacaterol is a long-acting beta-2-agonist bronchodilatorrecentlyapproved for usein COPD, whose maincharacteristicreferred toby manufacturersa rapid onset ofaction.Objective: To evaluatethe acute effect ofindacaterolin COPD patients. Methods: A randomized,double-blind, placebo-controlled study was conducted, using150 mcginhaledindacaterolin patients withCOPD. The outcomes assessed wereFEV1 and FVC(obtained through spirometry), heart and respiratory rate,blood pressure, SpO2, dyspnea sensationandstep test. Results:Fortypatients were enrolled.It was observed thatnosignificantbronchodilationwas notedbetween the indacateroland Placebogroups at 5,15 and 30 minutesiscompared to theFEV1 orFVC.Statistical differenceswere notnoted forthesecondary variablesasSpO2(p =0.89), FR(p =0.88), HR (p =0.31), blood pressure (p =0.85), dyspnea(p =0.60) and number of stepsclimbedafter 6minutes (0.72). Conclusion:In patients withstableCOPDindacaterolproduced nochangesin the outcomes assessedwithin 30 minutesafter use.